Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Calderón‐Larrañaga, Amaia; Poblador‐Plou, Beatriz; González-Rubio, Francisca; Gimeno-Feliu, Luis Andrés; Díez, José María Abad; Prados‐Torres, Alexandra

doi:10.3399/bjgp12x659295

Cited by 176 publications

(153 citation statements)

References 27 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Das führt nicht selten zu einer Multimedikation, die dem behandelnden Arzt nicht bekannt ist und deshalb auch als verdeckte Multimedikation bezeichnet wird. Je mehr Präparate gleichzeitig eingenommen werden, desto größer ist das Risiko von Arzneimittelinteraktionen und unerwünschten Arzneimittelrisiken [7]. Vor diesem Hintergrund ergibt sich die Notwendigkeit des Monitorings der Anwendung von Arzneimitteln und NEM auf individueller und bevölkerungsbezo-gener Ebene.…”

Section: Hintergrund Und Zielstellungunclassified

Selbstmedikation mit Vitaminen, Mineralstoffen und Nahrungsergänzungsmitteln in Deutschland

Knopf

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

Section: Hintergrund Und Zielstellungunclassified

Selbstmedikation mit Vitaminen, Mineralstoffen und Nahrungsergänzungsmitteln in Deutschland

Knopf

2017

Bundesgesundheitsbl

View full text Add to dashboard Cite

“…Multimorbidity has been associated with several undesirable health outcomes including reductions in life expectancy [4], functional decline [5] and increases in the probability of adverse drug events [6]. The prevalence of multimorbidity involving physical chronic conditions only is similar among least and most socioeconomically deprived groups of older adults.…”

Section: Short Communicationmentioning

confidence: 99%

Multimorbidity and Health-Related Quality of Life among Older Adults

Aydede¹,

Rasali²,

Osei³

et al. 2017

J Gerontol Geriatr Res

View full text Add to dashboard Cite

“…One aspect of treatment burden described above is polypharmacy, which can contribute to other treatment burdens such as adverse drug events [12,13]. Polypharmacy is most commonly defined as the use of multiple (usually five or ten) prescribed medications [14][15][16].…”

Section: Introductionmentioning

confidence: 99%

Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden

Batty

McLean

et al. 2014

BMC Medicine

View full text Add to dashboard Cite

Background: The prevalence of multimorbidity (the presence of two or more long-term conditions) is rising internationally. Multimorbidity affects patients by increasing their burden of symptoms, but is also likely to increase the self-care demands, or treatment burden, that they experience. Treatment burden refers to the effort expended in operationalising treatments, navigating healthcare systems and managing relations with healthcare providers. This is an important problem for people with chronic illness such as stroke. Polypharmacy is an important marker of both multimorbidity and burden of treatment. In this study, we examined the prevalence of multimorbidity and polypharmacy in a large, nationally representative population of primary care patients with and without stroke, adjusting for age, sex and deprivation. Methods: A cross-sectional study of 1,424,378 participants aged 18 years and over, from 314 primary care practices in Scotland that were known to be demographically representative of the Scottish adult population. Data included information on the presence of stroke and another 39 long-term conditions, plus prescriptions for regular medications. Results: In total, 35,690 people (2.5%) had a diagnosis of stroke. Of the 39 comorbidities examined, 35 were significantly more common in people with stroke. Of the people with a stroke, the proportion that had one or more additional morbidities present (94.2%) was almost twice that in the control group (48%) (odds ratio (OR) adjusted for age, sex and socioeconomic deprivation 5.18; 95% confidence interval (CI) 4.95 to 5.43). In the stroke group, 12.6% had a record of 11 or more repeat prescriptions compared with only 1.5% of the control group (OR adjusted for age, sex, deprivation and morbidity count 15.84; 95% CI 14.86 to 16.88). Limitations include the use of data collected for clinical rather than research purposes, a lack of consensus in the literature on the definition of certain long-term conditions, and the absence of statistical weighting in the measurement of multimorbidity, although the latter was deemed suitable for descriptive analyses. Conclusions: Multimorbidity and polypharmacy were strikingly more common in those with a diagnosis of stroke compared with those without. This has important implications for clinical guidelines and the design of health services.

show abstract

Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?

Cited by 176 publications

References 27 publications

Selbstmedikation mit Vitaminen, Mineralstoffen und Nahrungsergänzungsmitteln in Deutschland

Selbstmedikation mit Vitaminen, Mineralstoffen und Nahrungsergänzungsmitteln in Deutschland

Multimorbidity and Health-Related Quality of Life among Older Adults

Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden

Contact Info

Product

Resources

About